Skip to main content
Top
Published in: Journal of Translational Medicine 1/2014

Open Access 01-12-2014 | Research

Non-traditional CD4+CD25−CD69+ regulatory T cells are correlated to leukemia relapse after allogeneic hematopoietic stem cell transplantation

Authors: Xiao-su Zhao, Xu-hua Wang, Xiang-yu Zhao, Ying-jun Chang, Lan-ping Xu, Xiao-hui Zhang, Xiao-jun Huang

Published in: Journal of Translational Medicine | Issue 1/2014

Login to get access

Abstract

Background

Non-traditional CD4+CD25–CD69+ T cells were found to be involved in disease progression in tumor-bearing mouse models and cancer patients recently. We attempted to define whether this subset of T cells were related to leukemia relapse after allogeneic hematopoietic cell transplantation (allo-HSCT).

Methods

The frequency of CD4+CD25–CD69+ T cells among the CD4+ T cell population from the bone marrow of relapsed patients, patients with positive minimal residual disease (MRD+) and healthy donors was examined by flow cytometry. The CD4+CD25-CD69+ T cells were also stained with the intracellular markers to determine the cytokine (TGF-β, IL-2 and IL-10) secretion.

Results

The results showed that the frequency of CD4+CD25–CD69 + T cells was markedly increased in patients in the relapsed group and the MRD + group compared to the healthy donor group. The percentage of this subset of T cells was significantly decreased after effective intervention treatment. We also analyzed the reconstitution of CD4+CD25–CD69+ T cells at various time points after allo-HSCT, and the results showed that this subset of T cells reconstituted rapidly and reached a relatively higher level at +60 d in patients compared to controls. The incidence of either MRD+ or relapse in patients with a high frequency of CD4+CD25-CD69+ T cells (>7%) was significantly higher than that of patients with a low frequency of CD4+CD25-CD69+ T cells at +60 d, +90 d and +270 d after transplant. However, our preliminary data indicated that CD4+CD25-CD69+ T cells may not exert immunoregulatory function via cytokine secretion.

Conclusions

This study provides the first clinical evidence of a correlation between non-traditional CD4+CD25-CD69+ Tregs and leukemia relapse after allo-HSCT and suggests that exploration of new methods of adoptive immunotherapy may be beneficial. Further research related to regulatory mechanism behind this phenomenon would be necessary.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sakaguchi S: Regulatory T cells in the past and for the future. Eur J Immunol. 2008, 38: 901-937. 10.1002/eji.200890012.CrossRefPubMed Sakaguchi S: Regulatory T cells in the past and for the future. Eur J Immunol. 2008, 38: 901-937. 10.1002/eji.200890012.CrossRefPubMed
2.
go back to reference Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995, 155: 1151-1164.PubMed Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995, 155: 1151-1164.PubMed
3.
go back to reference Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH, Rubinstein P, McGlave PB, Blazar BR, Wagner JE: Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011, 117: 1061-1070. 10.1182/blood-2010-07-293795.PubMedCentralCrossRefPubMed Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH, Rubinstein P, McGlave PB, Blazar BR, Wagner JE: Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011, 117: 1061-1070. 10.1182/blood-2010-07-293795.PubMedCentralCrossRefPubMed
4.
go back to reference Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH, Cornelissen JJ, Schattenberg AV: The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood. 2004, 103: 4362-4364. 10.1182/blood-2003-11-3862.CrossRefPubMed Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH, Cornelissen JJ, Schattenberg AV: The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood. 2004, 103: 4362-4364. 10.1182/blood-2003-11-3862.CrossRefPubMed
5.
go back to reference Mutis T, van Rijn RS, Simonetti ER, Aarts-Riemens T, Emmelot ME, van Bloois L, Martens A, Verdonck LF, Ebeling SB: Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2−/−gammac−/− immunodeficient mice. Clin Cancer Res. 2006, 12: 5520-5525. 10.1158/1078-0432.CCR-06-0035.CrossRefPubMed Mutis T, van Rijn RS, Simonetti ER, Aarts-Riemens T, Emmelot ME, van Bloois L, Martens A, Verdonck LF, Ebeling SB: Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2−/−gammac−/− immunodeficient mice. Clin Cancer Res. 2006, 12: 5520-5525. 10.1158/1078-0432.CCR-06-0035.CrossRefPubMed
6.
go back to reference Soiffer R: Immune modulation and chronic graft-versus-host disease. Bone Marrow Transplant. 2008, 42 (Suppl 1): S66-S69.CrossRefPubMed Soiffer R: Immune modulation and chronic graft-versus-host disease. Bone Marrow Transplant. 2008, 42 (Suppl 1): S66-S69.CrossRefPubMed
7.
go back to reference Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B: Graft-versus-myeloma effect: proof of principle. Blood. 1996, 87: 1196-1198.PubMed Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B: Graft-versus-myeloma effect: proof of principle. Blood. 1996, 87: 1196-1198.PubMed
8.
go back to reference Rabinovich GA, Gabrilovich D, Sotomayor EM: Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007, 25: 267-296. 10.1146/annurev.immunol.25.022106.141609.PubMedCentralCrossRefPubMed Rabinovich GA, Gabrilovich D, Sotomayor EM: Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007, 25: 267-296. 10.1146/annurev.immunol.25.022106.141609.PubMedCentralCrossRefPubMed
9.
go back to reference Wang HY, Wang RF: Regulatory T cells and cancer. Curr Opin Immunol. 2007, 19: 217-223. 10.1016/j.coi.2007.02.004.CrossRefPubMed Wang HY, Wang RF: Regulatory T cells and cancer. Curr Opin Immunol. 2007, 19: 217-223. 10.1016/j.coi.2007.02.004.CrossRefPubMed
10.
go back to reference Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006, 6: 295-307. 10.1038/nri1806.CrossRefPubMed Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006, 6: 295-307. 10.1038/nri1806.CrossRefPubMed
11.
go back to reference Buckner JH, Ziegler SF: Regulating the immune system: the induction of regulatory T cells in the periphery. Arthritis Res Ther. 2004, 6: 215-222. 10.1186/ar1226.PubMedCentralCrossRefPubMed Buckner JH, Ziegler SF: Regulating the immune system: the induction of regulatory T cells in the periphery. Arthritis Res Ther. 2004, 6: 215-222. 10.1186/ar1226.PubMedCentralCrossRefPubMed
12.
go back to reference Ziegler SF: FOXP3: of mice and men. Annu Rev Immunol. 2006, 24: 209-226. 10.1146/annurev.immunol.24.021605.090547.CrossRefPubMed Ziegler SF: FOXP3: of mice and men. Annu Rev Immunol. 2006, 24: 209-226. 10.1146/annurev.immunol.24.021605.090547.CrossRefPubMed
13.
go back to reference Lan RY, Ansari AA, Lian ZX, Gershwin ME: Regulatory T cells: development, function and role in autoimmunity. Autoimmun Rev. 2005, 4: 351-363. 10.1016/j.autrev.2005.01.007.CrossRefPubMed Lan RY, Ansari AA, Lian ZX, Gershwin ME: Regulatory T cells: development, function and role in autoimmunity. Autoimmun Rev. 2005, 4: 351-363. 10.1016/j.autrev.2005.01.007.CrossRefPubMed
14.
go back to reference Han Y, Guo Q, Zhang M, Chen Z, Cao X: CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immunol. 2009, 182: 111-120. 10.4049/jimmunol.182.1.111.CrossRefPubMed Han Y, Guo Q, Zhang M, Chen Z, Cao X: CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immunol. 2009, 182: 111-120. 10.4049/jimmunol.182.1.111.CrossRefPubMed
15.
go back to reference Zhu J, Feng A, Sun J, Jiang Z, Zhang G, Wang K, Hu S, Qu X: Increased CD4(+) CD69(+) CD25(−) T cells in patients with hepatocellular carcinoma are associated with tumor progression. J Gastroenterol Hepatol. 2011, 26: 1519-1526. 10.1111/j.1440-1746.2011.06765.x.CrossRefPubMed Zhu J, Feng A, Sun J, Jiang Z, Zhang G, Wang K, Hu S, Qu X: Increased CD4(+) CD69(+) CD25(−) T cells in patients with hepatocellular carcinoma are associated with tumor progression. J Gastroenterol Hepatol. 2011, 26: 1519-1526. 10.1111/j.1440-1746.2011.06765.x.CrossRefPubMed
16.
go back to reference Lu SY, Huang XJ, Liu KY, Liu DH, Xu LP: High frequency of CD4+ CD25–CD69+ T cells is correlated with a low risk of acute graft-versus-host disease in allotransplants. Clin Transplant. 2012, 26: E158-E167. 10.1111/j.1399-0012.2012.01630.x.CrossRefPubMed Lu SY, Huang XJ, Liu KY, Liu DH, Xu LP: High frequency of CD4+ CD25–CD69+ T cells is correlated with a low risk of acute graft-versus-host disease in allotransplants. Clin Transplant. 2012, 26: E158-E167. 10.1111/j.1399-0012.2012.01630.x.CrossRefPubMed
17.
go back to reference Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Wang JZ, Gao ZY, Zhang YC, Jiang Q, Shi HX, Lu DP: Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006, 38: 291-297. 10.1038/sj.bmt.1705445.CrossRefPubMed Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Wang JZ, Gao ZY, Zhang YC, Jiang Q, Shi HX, Lu DP: Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006, 38: 291-297. 10.1038/sj.bmt.1705445.CrossRefPubMed
18.
go back to reference Huang XJ, Wang Y, Liu DH, Xu LP, Chen H, Chen YH, Han W, Shi HX, Liu KY: Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia–feasibility and safety study. J Clin Immunol. 2008, 28: 390-397. 10.1007/s10875-008-9193-4.CrossRefPubMed Huang XJ, Wang Y, Liu DH, Xu LP, Chen H, Chen YH, Han W, Shi HX, Liu KY: Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia–feasibility and safety study. J Clin Immunol. 2008, 28: 390-397. 10.1007/s10875-008-9193-4.CrossRefPubMed
19.
go back to reference Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, Han W, Wang Y, Qin YZ, Huang XJ: Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012, 119: 3256-3262. 10.1182/blood-2011-09-380386.CrossRefPubMed Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, Han W, Wang Y, Qin YZ, Huang XJ: Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012, 119: 3256-3262. 10.1182/blood-2011-09-380386.CrossRefPubMed
20.
go back to reference Colombo MP, Piconese S: Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer. 2007, 7: 880-887. 10.1038/nrc2250.CrossRefPubMed Colombo MP, Piconese S: Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer. 2007, 7: 880-887. 10.1038/nrc2250.CrossRefPubMed
21.
go back to reference Feunou P, Poulin L, Habran C, Le Moine A, Goldman M, Braun MY: CD4+CD25+ and CD4+CD25- T cells act respectively as inducer and effector T suppressor cells in superantigen-induced tolerance. J Immunol. 2003, 171: 3475-3484. 10.4049/jimmunol.171.7.3475.CrossRefPubMed Feunou P, Poulin L, Habran C, Le Moine A, Goldman M, Braun MY: CD4+CD25+ and CD4+CD25- T cells act respectively as inducer and effector T suppressor cells in superantigen-induced tolerance. J Immunol. 2003, 171: 3475-3484. 10.4049/jimmunol.171.7.3475.CrossRefPubMed
22.
go back to reference Stephens LA, Mason D: CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25- subpopulations. J Immunol. 2000, 165: 3105-3110. 10.4049/jimmunol.165.6.3105.CrossRefPubMed Stephens LA, Mason D: CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25- subpopulations. J Immunol. 2000, 165: 3105-3110. 10.4049/jimmunol.165.6.3105.CrossRefPubMed
23.
go back to reference Graca L, Thompson S, Lin CY, Adams E, Cobbold SP, Waldmann H: Both CD4(+)CD25(+) and CD4(+)CD25(−) regulatory cells mediate dominant transplantation tolerance. J Immunol. 2002, 168: 5558-5565. 10.4049/jimmunol.168.11.5558.CrossRefPubMed Graca L, Thompson S, Lin CY, Adams E, Cobbold SP, Waldmann H: Both CD4(+)CD25(+) and CD4(+)CD25(−) regulatory cells mediate dominant transplantation tolerance. J Immunol. 2002, 168: 5558-5565. 10.4049/jimmunol.168.11.5558.CrossRefPubMed
24.
go back to reference Degauque N, Lair D, Braudeau C, Haspot F, Sebille F, Dupont A, Merieau E, Brouard S, Soulillou JP: Development of CD25- regulatory T cells following heart transplantation: evidence for transfer of long-term survival. Eur J Immunol. 2007, 37: 147-156. 10.1002/eji.200635879.CrossRefPubMed Degauque N, Lair D, Braudeau C, Haspot F, Sebille F, Dupont A, Merieau E, Brouard S, Soulillou JP: Development of CD25- regulatory T cells following heart transplantation: evidence for transfer of long-term survival. Eur J Immunol. 2007, 37: 147-156. 10.1002/eji.200635879.CrossRefPubMed
25.
go back to reference Luyckx A, Schouppe E, Rutgeerts O, Lenaerts C, Koks C, Fevery S, Devos T, Dierickx D, Waer M, Van Ginderachter JA, Billiau AD: Subset characterization of myeloid-derived suppressor cells arising during induction of BM chimerism in mice. Bone Marrow Transplant. 2012, 47: 985-992. 10.1038/bmt.2011.207.CrossRefPubMed Luyckx A, Schouppe E, Rutgeerts O, Lenaerts C, Koks C, Fevery S, Devos T, Dierickx D, Waer M, Van Ginderachter JA, Billiau AD: Subset characterization of myeloid-derived suppressor cells arising during induction of BM chimerism in mice. Bone Marrow Transplant. 2012, 47: 985-992. 10.1038/bmt.2011.207.CrossRefPubMed
26.
go back to reference Mougiakakos D, Jitschin R, von Bahr L, Poschke I, Gary R, Sundberg B, Gerbitz A, Ljungman P, Le Blanc K: Immunosuppressive CD14+HLA-DRlow/neg IDO + myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia. 2013, 27: 377-388. 10.1038/leu.2012.215.CrossRefPubMed Mougiakakos D, Jitschin R, von Bahr L, Poschke I, Gary R, Sundberg B, Gerbitz A, Ljungman P, Le Blanc K: Immunosuppressive CD14+HLA-DRlow/neg IDO + myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia. 2013, 27: 377-388. 10.1038/leu.2012.215.CrossRefPubMed
Metadata
Title
Non-traditional CD4+CD25−CD69+ regulatory T cells are correlated to leukemia relapse after allogeneic hematopoietic stem cell transplantation
Authors
Xiao-su Zhao
Xu-hua Wang
Xiang-yu Zhao
Ying-jun Chang
Lan-ping Xu
Xiao-hui Zhang
Xiao-jun Huang
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2014
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-12-187

Other articles of this Issue 1/2014

Journal of Translational Medicine 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.